Full-Time

Field Reimbursement Manager

East and South

Posted on 9/12/2025

Coherus BioSciences

Coherus BioSciences

201-500 employees

Develops and commercializes biosimilar biologics

Compensation Overview

$165k - $190k/yr

United States

In Person

Category
Operations & Logistics (1)
Requirements
  • 5+ years of commercial experience in the pharmaceutical or biotech industry
  • 3+ years of experience in healthcare coverage, coding and/or reimbursement
  • Direct experience with Buy and Bill products, Medicare Part B and Miscellaneous J-Codes required
  • Bachelor's degree from a four-year college or university
  • Previous experience working with billing and medical claims personnel in various health care settings, including physician office, hospital, HOPD and ASC
  • Shown expertise in supporting healthcare provider offices with coding, billing, and submissions in range of payer environments
  • Well versed with implementing and executing Medicare, Medicaid, and other payer initiatives
  • Familiar with CPT, HCPCS, ICD-10 revenue codes
  • Familiarity with health insurance claim forms, explanation of benefits, prior authorization forms, and EMR/Practice Mgmt. systems, to troubleshoot cases where billing, claims submission or documentation errors may occur
  • Ability to analyze, interpret and understand regulatory and legislative payer and healthcare policies
  • Candidate must reside within assigned territory and have the ability to travel up to 70%
Responsibilities
  • Partner with internal and external stakeholders to identify, anticipate and address patient and practice reimbursement issues
  • Collaborate with Field Sales to identify facilities and practices that need reimbursement education and support regarding Coherus products
  • Provide insights and updates regarding product and support service integration at accounts
  • Educate facility staff on policies related to product acquisition, inventory management, and all payer polices related to support full integration of product into the practice workflow
  • Provide coverage, coding, and reimbursement information to key staff members (i.e., practice administrators, reimbursement staff, and providers) in order to appropriately support patient access
  • Collaborate with field facing “One Team” to compliantly share insights into customer needs, potential barriers, and payer issues/opportunities for access at practices
  • Communicate and explain payer policy updates or system changes that impact access
  • Proactively communicate Coherus COMPLETE™ so that office staff is fluent in how to use patient access programs and services
  • Address questions associated with patient coverage, access, and reimbursement from accounts in collaboration and coordination with patient services as directed by policy and procedure
  • Conduct frequent claim reviews with practices to ensure appropriate reimbursement of Coherus products
  • Maintain a deep understanding of Coherus policies and requirements and perform the role in a compliant manner consistent with company guidance
  • Keep abreast of customer and market access industry trends
Desired Qualifications
  • Oncology experience strongly preferred

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines. These products are created through biotechnology to match the safety and effectiveness of the original biologics while offering lower prices. Coherus’ products are designed to provide patients and healthcare systems with more affordable access to essential biologic treatments and to offset rising healthcare costs. The company differentiates itself by focusing on high-quality biosimilars and a rigorous regulatory pathway to ensure similar efficacy and safety to the originals, enabling broader adoption among providers, hospitals, and patients. Its goal is to improve patient lives by expanding access to life-changing biologic medicines and making treatments more affordable.

Company Size

201-500

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • LOQTORZI revenue doubled to $40.8M in 2025, targeting $175M run-rate by 2028.
  • Debt slashed 90% from $480M to $38.8M, saving $15M annual interest.
  • $50M raised February 2026 funds LOQTORZI commercialization and pipeline.

What critics are saying

  • Commercial chief exit stalls LOQTORZI Q1 2026 sales ramp to $15M quarterly.
  • Apotex deal transfers Canadian toripalimab rights, eroding North American revenue.
  • Keytruda dominance caps LOQTORZI below $30M quarterly breakeven in 18 months.

What makes Coherus BioSciences unique

  • Pioneers next-generation PD-1 inhibitor LOQTORZI for nasopharyngeal carcinoma.
  • Advances Tagmokitug anti-CCR8 and casdozokitug IL-27 antibodies in oncology pipeline.
  • Transforms from biosimilars to innovative immuno-oncology combination therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Coherus BioSciences who can refer or advise you

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-1%
Yahoo Finance
Mar 10th, 2026
Coherus Oncology doubles LOQTORZI revenue to $41M, slashes debt by 90% to $39M

Coherus Oncology has reported strong revenue growth for 2025, with its drug LOQTORZI achieving net revenue of $40.8 million, a 113% increase from $19.1 million in 2024. Fourth-quarter revenue reached $12.4 million, marking an 11% growth over the third quarter. The company significantly improved its financial position by reducing debt by over 90%, from $480 million to $38.8 million by year-end 2025. This resulted in interest cost savings of over $15 million. The firm also cut headcount by 35% and reduced selling, general and administrative expenses to $23.6 million in Q4 from $29.6 million the previous year. Coherus ended 2025 with $172.1 million in cash and investments whilst developing two promising product candidates, Tagmokitug and casdozokitug.

Yahoo Finance
Mar 8th, 2026
Coherus cuts debt 90%, LOQTORZI sales double in 2025, eyes $175M annual run rate by 2028

Coherus Oncology has reduced its debt by approximately 90%, cutting it from $480 million to $3.7 million in senior secured debt, whilst adding $250 million to its balance sheet through biosimilar asset divestitures following its 2023 Surface Oncology acquisition. The company reported accelerating sales of LOQTORZI, its PD-1 therapy for nasopharyngeal carcinoma, with 2025 sales doubling from 2024's $19 million. Management expects quarterly sales to reach $15 million to $16 million in 2026, covering the commercial team's costs, and projects a long-term run rate of roughly $175 million annually by 2028. Coherus aims to achieve cash-flow breakeven, excluding clinical trial costs, when quarterly sales exceed $30 million. The company has scheduled clinical data readouts for two pipeline assets in 2026.

MarketScreener
Feb 13th, 2026
Coherus Oncology prices $50M public offering at $1.75 per share to fund LOQTORZI commercialisation

Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share. The company expects to raise approximately $50.1 million in gross proceeds before underwriting discounts and expenses. The offering includes a 30-day option for underwriters to purchase an additional 4.29 million shares. The transaction is expected to close on 17 February 2026. Coherus plans to use the net proceeds to support commercialisation of LOQTORZI, continue clinical development of product candidates, and for working capital and general corporate purposes. The commercial-stage oncology company has an approved PD-1 inhibitor and a pipeline targeting liver, prostate, head and neck, and colorectal cancers. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners.

Coherus Oncology
Jan 6th, 2026
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Coherus management to present at the 44th Annual J.P. Morgan Healthcare Conference. REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) - Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until February 13, 2026. About Coherus Oncology Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI(R)(toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, colorectal and other cancers. The Company's strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations. Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma. For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.

PharmiWeb.com
May 28th, 2025
Storm Therapeutics Announces First Patient Dosed In Clinical Collaboration To Evaluate Stc-15 In Combination With Loqtorzi® And Appointment Of Atif Abbas, M.D., As Chief Medical Officer

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer. STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor

INACTIVE